文献速递血栓与止血

HEAD-US-C超声评估量表评估中重型血友病A按需与预防治疗患者关节损伤

[HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

回顾性分析2015年6月至2017年7月70例中间型及重型血友病A患者,应用HEAD-US-C量表与HJHS2.1评分评估关节状况。预防治疗疗效明显优于按需治疗,HEAD-US-C与HJHS评分呈正相关,可为临床疗效评估提供客观指标。

要点

  • 中间型患者按需组HEAD-US-C和HJHS评分均高于预防组
  • 重型患者按需组HEAD-US-C评分、HJHS评分及年靶关节出血次数均高于预防组
  • HEAD-US-C与HJHS评分正相关,预防组相关性更强

核心结论

  • 中间型/重型血友病A患者预防治疗疗效明显优于按需治疗。
  • HEAD-US-C超声评估量表可有效评估中间型/重型血友病A患者按需、预防治疗关节损伤状况,与HJHS系统一致性较好,可为临床疗效评估提供客观指标。

研究设计与样本

  • 回顾性分析2015年6月至2017年7月70例接受肘、膝、踝关节超声检查的中间型及重型血友病A患者。
  • 应用HEAD-US-C超声评估量表及血友病关节健康评分量表2.1版(HJHS2.1)进行关节状况评分,对按需、预防治疗患者HEAD-US-C、HJHS评分进行相关性分析。

主要发现

  • 70例患者共接受919例次关节超声检查。
  • 中间型患者按需组与预防组中位年靶关节出血次数差异无统计学意义[1(0,7)对1(0,5),z=1.271,P=0.137]。
  • 中间型患者按需组中位HEAD-US-C评分[1(0,6)对0.5(0,3),z=0.177,P=0.046]及HJHS评分[2(0,4)对2(0,3),z=0.375,P=0.007]明显高于预防组。
  • 重型患者按需组与预防组中位HEAD-US-C评分分别为4(0,7)、1(0,6)(z=2.189,P=0.008),中位HJHS评分分别为4(1,6)、2(0,5)(z=3.646,P<0.001),年靶关节出血次数分别为3(0,8)、2(0,8)(z=0.780,P=0.037),按需组均高于预防组。
  • 按需、预防治疗组患者HEAD-US-C评分与HJHS评分均存在正相关关系(P值均<0.05);重型患者按需、预防治疗组相关系数分别为0.739(95%CI 0.708~0.767)、0.865(95%CI 0.848~0.880),95%CI不重合(P<0.05),预防治疗组两评分系统间具有更强的相关性。

关键数值与推荐

  • 中间型患者按需组中位HEAD-US-C评分1(0,6)对预防组0.5(0,3),P=0.046。
  • 中间型患者按需组中位HJHS评分2(0,4)对预防组2(0,3),P=0.007。
  • 重型患者按需组中位HEAD-US-C评分4(0,7)对预防组1(0,6),P=0.008。
  • 重型患者按需组中位HJHS评分4(1,6)对预防组2(0,5),P<0.001。
  • 重型患者按需组年靶关节出血次数3(0,8)对预防组2(0,8),P=0.037。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the evaluation of joint injury by HEAD-US-C (Hemophilic Early Arthropathy Detection with UltraSound in China, HEAD-US-C) in patients with moderate or severe hemophilia A treated with prophylaxis vs on-demand. Methods: The patients from June 2015 to July 2017 with moderate or severe hemophilia A were examined by ultrasound imaging of the elbows, knees and ankles; Meanwhile the HEAD-US-C ultrasound assessment scale and hemophilia joint health score scale 2.1 (HJHS2.1) were used to score the joint status. The correlation between the HEAD-US-C and HJHS score was performed in prophylaxis group and on-demand group patients, respectively. Results: A total of 925 cases of joint ultrasonography were conducted in 70 patients with moderate or severe hemophilia A. Among patients with moderate hemophilia, the median (IQR) of HEAD-US-C score and HJHS score in on-demand group were significantly higher than those in the prophylaxis group[1 (0, 6) vs 0.5 (0, 3) , z=0.177, P=0.046],[2 (0, 4) vs 2 (0, 3) z=0.375, P=0.007], even though there was no significant difference of the median (IQR) number of annualized target joints bleeding episodes between on-demand and prophylaxis groups[1 (0, 7) vs 1 (0, 5) , z=1.271, P=0.137]. Unlike in moderate cases, on-demand treatment group had more annualized target joints bleeding episodes than prophylaxis group among patients with severe hemophilia[3 (0, 8) vs 2 (0, 8) , z=0.780 P=0.037]. The prophylaxis group compared favorably with on-demand therapy group in terms of HEAD-US-C score[1 (0, 6) vs 4 (0, 7) , z=2.189, P=0.008], and HJHS score[2 (0, 5) , 4 (1, 6) , z=3646, P<0.001]for the severe hemophilia patients. The positive correlation between HEAD-US-C score and HJHS score was identified (P<0.05) , whether on-demand treatment or prophylaxis groups. The correlation coefficient between HEAD-US-C score and HJHS score in on-demand treatment and prophylaxis groups were 0.739 (95% CI 0.708-0.708) , 0.865 (95% CI 0.848-0.848) respectively, and 95% CI didn't overlap (P<0.05) , indicating that the correlation coefficient in prophylaxis group had stronger correlation than that in on-demand group. Conclusions: Clinical effects of prophylaxis were significantly better than those of on-demand treatment in patients with moderate or se-vere haemophilia A. HEAD-US-C scoring system could effectively evaluate joints damage in hemophilia A patients treated with on-demand or prophylaxis, companied by significantly positive correlation with HJHS clinical evaluation system, and provided objective index for clinical effect assessment. 目的: 探讨血友病关节超声评估量表(Haemophilic Early Arthropathy Detection with UltraSound in China,HEAD-US-C)对中间型/重型血友病A患者按需、预防治疗关节损伤评估的适用性。 方法: 回顾性分析2015年6月至2017年7月70例接受肘、膝、踝关节超声检查的中间型及重型血友病A患者,应用HEAD-US-C超声评估量表及血友病关节健康评分量表2.1版(HJHS2.1)进行关节状况评分。对按需、预防治疗患者HEAD-US-C、HJHS评分进行相关性分析。 结果: 70例中间型及重型血友病A患者共接受919例次关节超声检查。在中间型血友病患者中,按需、预防治疗组患者中位年靶关节出血次数差异无统计学意义[1(0,7)对1(0,5),z=1.271,P=0.137]。按需治疗组中位HEAD-US-C评分[1(0,6)对0.5(0,3),z=0.177,P=0.046]及HJHS评分[2(0,4)对2(0,3),z=0.375,P=0.007]明显高于预防治疗组。重型血友病患者按需、预防治疗组中位HEAD-US-C评分分别为4(0,7)、1(0,6)(z=2.189,P=0.008),中位HJHS评分分别为4(1,6)、2(0,5)(z=3.646,P<0.001),年靶关节出血次数分别为3(0,8)、2(0,8)(z=0.780,P=0.037),按需治疗组均高于预防治疗组。按需、预防治疗组患者HEAD-US-C评分与HJHS评分均存在正相关关系(P值均<0.05)。重型患者按需、预防治疗组HEAD-US-C评分与HJHS评分的相关系数分别为0.739(95%CI 0.708~0.767)、0.865(95%CI 0.848~0.880),95%CI不重合(P<0.05),预防治疗组两评分系统间具有更强的相关性。 结论: 中间型/重型血友病A患者预防治疗疗效明显优于按需治疗。HEAD-US-C超声评估量表可有效评估中间型/重型血友病A患者按需、预防治疗关节损伤状况,与HJHS系统一致性较好,可为临床疗效评估提供客观指标。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li J, Liu W, Guo XJ, et al. [HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30369202. doi:10.3760/cma.j.issn.0253-2727.2018.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。